84 related articles for article (PubMed ID: 17633460)
1. [Design and activity determination of small molecular inhibitors of integrin alphavbeta3].
Ji Q; Zhou Y; Peng H; Huang N; Qi J; Xiong DS; Gao YD; Yang M; Yang CZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Jun; 29(3):347-52. PubMed ID: 17633460
[TBL] [Abstract][Full Text] [Related]
2. Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.
Zhou Y; Peng H; Ji Q; Qi J; Zhu Z; Yang C
Bioorg Med Chem Lett; 2006 Nov; 16(22):5878-82. PubMed ID: 16982193
[TBL] [Abstract][Full Text] [Related]
3. Integrin alphavbeta3 is not significantly implicated in the anti-migratory effect of anti-angiogenic urokinase kringle domain.
O E; Kim HK; Hong SH; Kim CK; Hong YK; Joe YA
Oncol Rep; 2008 Sep; 20(3):631-6. PubMed ID: 18695916
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacophore model of integrin alphavbeta3 antagonists].
Cheng GY; Ni GH; Jiang FC
Yao Xue Xue Bao; 2009 Apr; 44(4):379-85. PubMed ID: 19545055
[TBL] [Abstract][Full Text] [Related]
5. Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents.
Dayam R; Aiello F; Deng J; Wu Y; Garofalo A; Chen X; Neamati N
J Med Chem; 2006 Jul; 49(15):4526-34. PubMed ID: 16854058
[TBL] [Abstract][Full Text] [Related]
6. Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of betaig-h3, via alphavbeta3 integrin.
Nam JO; Jeong HW; Lee BH; Park RW; Kim IS
Cancer Res; 2005 May; 65(10):4153-61. PubMed ID: 15899806
[TBL] [Abstract][Full Text] [Related]
7. [Molecular design and biological activity of BCR-ABL tyrosine kinase inhibitors].
Peng H; Qi J; Huang N; Xie P; Wang JX; Yang CZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):145-9. PubMed ID: 15171550
[TBL] [Abstract][Full Text] [Related]
8. Identification of an active site on the laminin alpha4 chain globular domain that binds to alphavbeta3 integrin and promotes angiogenesis.
Lian J; Dai X; Li X; He F
Biochem Biophys Res Commun; 2006 Aug; 347(1):248-53. PubMed ID: 16824487
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics.
Gentilucci L; Cardillo G; Spampinato S; Tolomelli A; Squassabia F; De Marco R; Bedini A; Baiula M; Belvisi L; Civera M
J Med Chem; 2010 Jan; 53(1):106-18. PubMed ID: 20055426
[TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival.
Mi J; Zhang X; Giangrande PH; McNamara JO; Nimjee SM; Sarraf-Yazdi S; Sullenger BA; Clary BM
Biochem Biophys Res Commun; 2005 Dec; 338(2):956-63. PubMed ID: 16256939
[TBL] [Abstract][Full Text] [Related]
11. A functional radioreceptor assay of alpha-V-beta-3 (alphavbeta3) inhibitors in plasma: application as an ex vivo pharmacodynamic model.
Chaikin MA; Marugan JJ; De Vries GW; Baciu P; Edelman J; Ni M; Tomczuk BE; Pan W; Guo Z; Anaclerio B; Leonard K; Eisennagel SH; Molloy CJ; Manthey CL
J Biochem Biophys Methods; 2005 Dec; 65(2-3):107-20. PubMed ID: 16325916
[TBL] [Abstract][Full Text] [Related]
12. Rhodostomin inhibits thrombin-enhanced adhesion of ROS 17/2.8 cells through the blockade of alphavbeta3 integrin.
Yang RS; Chiang HS; Tang CH; Yeh CS; Huang TF
Toxicon; 2005 Sep; 46(4):387-93. PubMed ID: 16051297
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist.
Mousa SA; Mohamed S; Wexler EJ; Kerr JS
Anticancer Res; 2005; 25(1A):197-206. PubMed ID: 15816539
[TBL] [Abstract][Full Text] [Related]
14. Tricyclic pharmacophore-based molecules as novel integrin alphavbeta3 antagonists. Part IV: preliminary control of alphavbeta3 selectivity by meta-oriented substitution.
Kubota D; Ishikawa M; Ishikawa M; Yahata N; Murakami S; Fujishima K; Kitakaze M; Ajito K
Bioorg Med Chem; 2006 Jun; 14(12):4158-81. PubMed ID: 16504518
[TBL] [Abstract][Full Text] [Related]
15. The integrin alpha5beta1 regulates alphavbeta3-mediated extracellular signal-regulated kinase activation.
Ly DP; Corbett SA
J Surg Res; 2005 Feb; 123(2):200-5. PubMed ID: 15680379
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein(a) stimulates vascular endothelial cell growth and migration and signals through integrin alphaVbeta3.
Liu L; Craig AW; Meldrum HD; Marcovina SM; Elliott BE; Koschinsky ML
Biochem J; 2009 Mar; 418(2):325-36. PubMed ID: 18821851
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of the αvβ3 integrin antagonist RGDechi-hCit on malignant melanoma cells.
Pisano M; DE Paola I; Nieddu V; Sassu I; Cossu S; Galleri G; Del Gatto A; Budroni M; Cossu A; Saviano M; Palmieri G; Zaccaro L; Rozzo C
Anticancer Res; 2013 Mar; 33(3):871-9. PubMed ID: 23482756
[TBL] [Abstract][Full Text] [Related]
18. Novel small molecule inhibitors for prostate-specific antigen.
Koistinen H; Wohlfahrt G; Mattsson JM; Wu P; Lahdenperä J; Stenman UH
Prostate; 2008 Aug; 68(11):1143-51. PubMed ID: 18500692
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists.
Presta M; Oreste P; Zoppetti G; Belleri M; Tanghetti E; Leali D; Urbinati C; Bugatti A; Ronca R; Nicoli S; Moroni E; Stabile H; Camozzi M; Hernandez GA; Mitola S; Dell'Era P; Rusnati M; Ribatti D
Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):71-6. PubMed ID: 15514208
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel angiogenesis inhibitors.
Sridhar J; Akula N; Sivanesan D; Narasimhan M; Rathinavelu A; Pattabiraman N
Bioorg Med Chem Lett; 2005 Sep; 15(18):4125-9. PubMed ID: 15993586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
